Editor - Prof. Noah Isakov | Ben Gurion University of Negev | 22810

Journal of Mucosal Immunology Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Journal of Mucosal Immunology Research peer review process verified at publons
Share This Page

Prof. Noah Isakov

Prof. Noah Isakov
Prof. Noah Isakov
The Shraga Segal Department of Microbiology
Immunology and Genetics
Faculty of Health Sciences 
Ben Gurion University of the Negev,
Ben Gurion University of Negev


Noah Isakov is a Professor of Immunology in the Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, at Ben Gurion University of the Negev, in Beer Sheva, Israel, where he holds the Joseph H Krupp Chair in Cancer Immunobiology. He obtained his PhD from the Weizmann Institute of Science in Rehovot, Israel (1981) and worked as a postdoctoral researcher at the University of Minnesota in Minneapolis, MN (1981-1983) and the Scripps Research Institute in La Jolla, CA (1983-1987). He performed sabbaticals at the NICHD, National Institutes of Health in Bethesda, MD (1993-1995), the Oklahoma Medical Research Foundation in Oklahoma City, OK (2003-2004), where he held the Esther Greenberg Honors Chair in Biomedical Research, and the Otago University in Dunedin, New Zealand (2015).

Research Interest

Our research focuses on various aspects of signal transduction in cells in general, and in T lymphocytes in particular. Studying mechanisms by which specific effector molecules regulate T cell activation, proliferation and differentiation will enable the design of new therapeutic modalities for attenuating undesired inflammatory responses and inhibit the growth of leukemic T cells.